Emily Pierce is a registered nurse with over 10 years of experience in oncology clinical research. She currently works as a Clinical Research Nurse/Coordinator at the James P. Wilmot Cancer Center, where she oversees multiple phase 1-3 oncology clinical trials. She has extensive experience in all aspects of clinical trial management including protocol development, regulatory compliance, patient enrollment, data collection and reporting. She also serves on several committees related to clinical research and nursing.

1. 1 Curriculum Vitae
Emilty R. Pierce RN OCN CCRC
Contact Information
125 Brook Street
Hilton, NY 14468
585-721-2599
Emily125@rochester.rr.com
Registered Nurse NYS License
Experience
July 1, 2010-Present James P. Wilmot Cancer Institute, University of Rochester, OCN, Clinical Research Nurse/CRA
Review all new research protocols to identify scope and intensity of Nursing needed and GCP.
Oncology Advisory Council Subject Matter Expert for eRecord Research Protocol Translations
Cancer Committee Member for Advance of Multidisciplinary Care
Celgene Pregnancy Prevention Program Counselor.
Lymphoma Nurse Liaison for SWOG Research Professionals Committee
eRecord Research Leader
ARCP Item Writer
Survivorship Advisory Committee Wilmot Cancer Institute
Implemented and Maintain Research Protocol translation for Beacon EMR system.
Implemented and Maintain Research Protocol summary sheets for nursing website.
Facilitate Nursing care in the Clinical Trials Office.
Liaison between Office of Research and Project Administration (ORPA), Office of Research Accounting and Costing Standards
(ORACS), Principal Investigator (PI), Industry representatives, and collaborating academic Institutions to assist in the development of
and manage budgets for Industry supported Investigator-Initiated research
Negotiate trial specific contract language
Provide professional direction with the planning, implementation, coordination, operation and evaluation of the oncology projects in
the Clinical Trials Office. Maintain a working knowledge of the area(s) of expertise by reviewing research literature and abstracts,
attending pertinent meetings and seminar, participate in the preparation of regulatory approvals and study documents.
Identifies and provides for scheduling of study events for patients enrolled.
Maintain patient data, such as consent forms, letters, and appointment notices.
Collect clinical data during all phases of care while patient is on-study, complete case report forms.
Assist with study audits conducted by independent monitors and federal and governmental agencies.
Prepare and collate patient study information, status reports, and updates as necessary for reporting on progress of patients enrolled in
studies in order to accomplish a timely completion.
Collaborate with personnel in other departments and facilities to implement patient activities. Consult regularly with attendings and
fellows involved with patients enrolled on studies.
Preparation of study documents and regulatory approvals. Review and/or edit study documents
Nursing Education regarding study medication, procedures and Clinical Trials.
July 1, 2007-July 1, 2010 University of Rochester Medical Center Rochester, New York
Clinical Research Nurse/CRA, Department of Medicine, Gastroenterology & Hepatology Unit
Maintain accurate source documentations for all aspects of studies. Track data as appropriate to study.
Collect data on patients entered into the study via interviews, questionnaire completion, chart review and specimen results.
Perform study visits as per study protocols.
Recruit and enroll potential volunteers, explain study in detail and review, inclusion/exclusion criteria with potential candidate.
Prepare and maintain documents for regulatory agencies. Participate in budget development and contract negotiation. Coordinate site
visits, feasibility studies, and site assessments. Oversee entering and maintenance of data.
Serve as liaison between regulatory agencies, sponsor and other research sites. Review monthly ledgers to validate charges and
revenues. Submit reimbursement requests to sponsors.
2005-2007 AAIR Research Rochester, New York
Clinical Research Nurse Coordinator and recruiter for research studies in osteoarthritis, rheumatoid arthritis, asthma and immunology.
2002-2005 Highland Hospital Rochester, New York
Med/Surg RN- acute care, cardiac, ventilator, telemetry step down unit.
Certifications
Human Subjects Protection Program #74440612H, expires May, 2018
Therakos Immune Cell Therapy Photopheresis System
Basic Dysrhythmia Program University of Rochester/Strong Health
Epidural Catheter Certification Program Highland Hospital
Certified Clinical Research Coordinator ACRP since March, 2008
CLASP Certified June, 2009
Celgene Pregnancy Prevention Counseling Program for Lenalidomide, Pomalidomide, Thalidomide 8/2011
ONS Chemotherapy & Biotherapy Provider/OCN Oncology Certified Nurse

2. 2 Curriculum Vitae
Emilty R. Pierce RN OCN CCRC
Professional Licensures
ONS Chemotherapy & Biotherapy Provider expiration 7/23/2016
Registered Professional Nurse, New York State #551488-1, expiration 12/2015
Academy of Clinical Research Professionals ACRP since March, 2008
Community Emergency Response Team (CERT) since November, 2008
eRecord Oncology Charting Tools Workgroup
Professional Commitees and Memberships
J. P. Wilmot Cancer Center Clinical Trials Office Protocol Review Committee
Wilmot Cancer Center Clinical Trials Office Data Safety Monitor Committee
Celgene Pregnancy Prevention Counseling Program for Lenalidomide, Pomalidomide, Thalidomide 8/2011
J. P. Wilmot Cancer Center Oncology Advisory Council SME eRecord Research Protocol Translations
Continuing Education
Environmental Health & Safety: Lab Safety Training, University of Rochester Medical Center
Conducting Clinical Trials Workshop, University of Rochester Medical Center
Continuous Learning for Administrators of Sponsored Programs (CLASP)
ONS Chemotherapy and Biotherapy Course
Fundamentals of Bone Marrow Transplant ONS
Clinical Trials CRA Training Course SWOG
Investigator Training Course Roswell Park Cancer Center
Patient Safety Certification
Research Studies July 2010-present, James P. Wilmot Cancer Center University of Rochester
Jonathan Friedberg MD, Principal Investigator, A Phase 1-2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-
C19 in Subjects with Refractory Aggressive Non-Hodgkin Lymphoma (NHL).
Marcus Noel MD, Principal Investigator, An International, Multi-Center, Double-Blind, Randomized, Phase III Trial of 90Y-
Clivatuzumab Tetraxetan plus Low-Dose Gemcitabine Versus Placebo plus Low-Dose Gemcitabine in Patients with Metastatic
(Stage IV) Pancreatic Adenocarcinoma Who Received at Least Two Prior Treatments (PANCRIT-1)
JJ, Ifthikharuddin MD, Principal Investigator, An Open-label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax® CD38)
(Anti-CD38Monoclonal Antibody) in Combination with Backbone Regimens for the Treatment of Subjects with Multiple
Myeloma
Paul Barr MD, Principal Investigator, Chung, Funkit MD A phase 1 trial of SGN-CD70A in patients with CD70-positive
malignancies
Paul Barr, MD, Principal Investigator, A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in
Subjects with B-cell Malignancies
Eric Kim, MD, Principal Investigator, A phase I study of tetrathiomolybdate (TM) in combination with carboplatin and
pemetrexed in chemo-naïve metastatic or recurrent non-squamous non-small cell lung cancer
Paul Barr MD, Principal Investigator, A Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton's Tyrosine
Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine,
and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell
Lymphoma
Mohamed Tejani MD, Principal Investigator, A phase 1b, open label study of dalantercept plus sorafenib in patients with
advanced hepatocellular carcinoma
Elizabeth Guancial MD, Principal Investigator, An Open-Label, Single-Arm, Phase 2 Study of Mocetinostat in Selected Patients
with Inactivating Alterations of Acetyltransferase Genes in Previously Treated Locally Advanced or Metastatic Urothelial
Carcinoma.
Carla Casulo MD, Principal Investigator, A Phase II, Open-label study evaluating the safety and efficacy of gdc-0199 (abt-199)
plus bendamustine plus rituximab (BR) in comparison with BR alone or gdc-0199 plus rituximab (R) in patients with relapsed
and refractory follicular non-hodgkin’s lymphoma
Mohame Tejani MD, Principal Investigator, Phase 1/2 study of pf-03084014 in combination with gemcitabine And nab-
paclitaxel in patients with previously untreated Metastatic pancreatic ductal adenocarcinoma

3. 3 Curriculum Vitae
Emilty R. Pierce RN OCN CCRC
Paul Barr MD, Principal Investigator, A Phase 1 Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB040093 in Subjects
with Previously Treated B-cell Malignancies
Paul Barr MD, Principal Investigator, A prospective randomized phase II trial of pazopanib (nsc #737754, ind #75648) versus placebo in
patients with progressive carcinoid tumors
Paul Barr MD, Principal Investigator, open-label, non-randomized, two arm study to determine the efficacy and safety of ABT-199 (GDC-
0199) in subjects with relapsed or refractory chronic lymphocytic leukemia
Aram Hezel MD, Principal Investigator, A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human
Hyaluronidase) Combined With nab-Paclitaxel Plus Gemcitabine Compared With nab-Paclitaxel Plus Gemcitabine in Subjects with Stage IV
Previously Untreated Pancreatic Cancer Halozyme
Mohamed Tejani MD, Principal Investigator, A Phase 2, Open Label Study of Dalantercept plus Sorafenib in Patients with Advanced
Hepatocellular Carcinoma
Carla Casulo MD, Principal Investigator, a phase IB/II, open-label study evaluating the safety and pharmacokinetics of GDC-0199
(ABT-199) in combination with rituximab (r) or obinutuzumab (g) plus Cyclophosphamide, doxorubicin, vincristine, and prednisone
(CHOP) in patients with b-cell non-hodgkin’s lymphoma (NHL) and DLBCL
Funkit Chung MD and Barr, Paul MD Principal Investigators, A phase 1 trial of SGN-CD70A in patients with CD70-positive
malignancies
David Dougherty MD, Principal Investigator, A Phase 2, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in
Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
Carla Casulo MD, Principal Investigator, A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects with Lymphoid
Malignancies
Mohamed Tejani MD, Principal Investigator, A randomized, double blind, placebo-controlled, multicenter phase III study of
regorafenib in patients with hepatocellular carcinoma (HCC) after sorafenib
David Dougherty MD, Principal Investigator, A Phase 2b, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in
Second- or Third-line Treatment of Subjects with Unresectable Pleural or Peritoneal Malignant Mesothelioma
Jonathan Friedberg MD, Principal Investigator, A phase 2 single-arm, open-label study of single-agent brentuximab vedotin for
front-line therapy of Hodgkin lymphoma (HL) in adults age 60 and above
Jonathan Friedberg MD, Principal Investigator, A randomized, double-blind, placebo-controlled, phase 3 study of brentuximab
vedotin and CHP (A+CHP) versus CHOP in the frontline treatment of patients with CD30-positive mature T-cell lymphomas
Chung Funkit MD, Principal Investigator , A Randomized, Phase 2, Open-Label Study Evaluating Dn24-02 As Adjuvant Therapy In
Subjects With High Risk Her2+ Urothelial Carcinoma
Aram Hezel MD, Principal Investigator, SWOG Ph II AZD6244 and MK-2206 vs mFOLFOX in pts w/ Metastatic pancreatic cancer
post chemotherapy.
Jonathan Friedberg MD, Principal Investigator , A Phase II Trial to Evaluate the Efficacy of Fostamatinib in Patients with Relapsed or
Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Deepak Sahasrabudhe, MD, Principal Investigator, ECOG A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4
Therapy Versus High-Dose Interferon α- 2b for Resected High-Risk Melanoma
Paul Barr MD, Principal Investigator, Phase 1b, Escalating Dose Study of AVL-292, a Bruton’s Tyrosine Kinase (Btk) Inhibitor, as
Monotherapy in Subjects with Relapsed and/or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and
Waldenstrom’s Macroglobulinemia
Deepak Saharabudhe, MD, A Phase 1b/2 Study of Docetaxel and Prednisone, with or without ISIS 183750 (an eIF4E Inhibitor), in
Patients with Castrate-Resistant Prostate Cancer
Jane Lievseld MD, Principal Investigator, - A Phase I study of decitabine in combination with escalating doses of rapamycin in
patients with relapsed or refractory acute myeloid leukemia
Paul Barr MD, Principal Investigator, An Open-Label, Multicenter, Phase Ib Trial Of GA101 (Ro5072759) In Combination With
Chemotherapy In Patients With Previously Untreated Chronic Lymphocytic Leukemia

4. 4 Curriculum Vitae
Emilty R. Pierce RN OCN CCRC
Aram Hezel MD, Principal Investigator, A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in
Previously Treated Patients with Stage IIIB or IV Non-Small Cell Lung Cancer
Paul Barr MD, Principal Investigator , CALGB10404 ,A Genetic Risk-Stratified, Randomized Phase Ii Study Of Four
Fludarabine/Antibody Combinations For Patients With Symptomatic, Previously Untreated Chronic Lymphocytic
Leukemia
Steven H. Berstein, MD, Principal Investigator, A Phase 2, Multicenter, Single-Arm, Open-Label Study To Determine
The Efficacy And Safety Of Single-Agent Lenalidomide (Revlimid®) In Patients With Mantle Cell NHL Who Have
Relapsed Or Progressed After Treatment With Bortezomib Or Are Refractory To Bortezomib
Deborah, Mulford, MD, Prinicipal Investigator, Phase II study of Epratuzamab (NSC-716711) in combination with
Cytarabine and Clofarabine for Patients with Relapsed or Refractory PH-negative Precusor B-Cell ALL
Jonathan Friedberg, MD., Principal Investigator, SPORE Phase I Trial of Carfilzomib (PR-171) in Combination with
Vorinostat (SAHA) in Patients with Relapsed/Refractory B-Cell Lymphomas
Aram Hezel, MD, Prinicipal Investigator A Phase 1b/2 Study Evaluating IPI-926 in Combination with Gemcitabine in
Patients with Metastatic Pancreatic Cancer
Jane L. Liesveld, M.D., Principal Investigator, A Phase I, Dose Escalation Study of Plerixafor in Combination with
Cytarabine and Daunorubicin in Patients with De Novo Acute Myeloid Leukemia
Aram Hezel, M.D., Principal Investigator, A randomized, open-label, multi-center phase II study to compare AUY922
with docetaxel or irinotecan in adult patients with advanced gastric cancer, who have progressed after one line of
chemotherapy
Alok A. Khorana, M.D., Principal Investigator, Phase II Study of Coagulation Factor VIIa Inhibitor PCI-27483 in
Pancreatic Cancer Patients Receiving Treatment with Gemcitabine
Jonathan Friedberg, M.D., Principal Investigator, A Phase 1/2a Study Evaluating the Safety, Pharmacokinetics, and
Efficacy of ABT-263 in Subjects with Relapsed or Refractory Lymphoid Malignancies
Deepak Sahasrabudhe MD, Principal Investigator, Phase II Study of RO4929097 (NSC-749225) in Advanced Melanoma
Manoj Agarwal, MD, Prinicipal Investigator, A Phase II Trial of MTOR Inhibitor Everlimos RAD001 in malignant
pleural Mesothelioma (MPM)
Aram Hezel, MD, Principal Investigator, A Phase II Study of Oxaliplatin, Capecitabine, Cetuximab and Radiation in Pre-
Operative Therapy of Rectal Cancer"
Michelle Shayne, MD, Principal Investigator, A Phase 1 Dose Escalation Study of MLN8237, an Aurora A Kinase
Inhibitor, in Adult Patients with Non-Hematological Malignancies, Followed by a Phase 2 of MLN8237 in Lung, Breast,
Head and Neck, or Gastroesophageal Malignancies
Charles W. Francis, MD, Principal Investigator ,A Prospective Randomized Multicenter Study of Dalteparin Prophylaxis
in high risk ambulatory cancer patients
Deborah Mulford M.D., Principal Investigator ,Phase 1 dose-ranging study of Ezatiostat hydrochloride (Telintra®,
TLK199 tablets) in combination with Lenalidomide (REVLIMID®) in patients with non-deletion (5q) LOW TO
intermediate-1 risk Myelodysplastic Syndrome (MDS)
Deepak Sahasrabudhe, MD Principal Investigator, A Phase II, Open-Label, Controlled, Randomized Study of the CDX-
1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients with Newly Diagnosed Muscle-Invasive
Bladder Cancer Expressing hCG-ß
Aram Hezel MD, Principal Investigator, A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus
Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)
Research Studies July 2007-July 2010, University of Rochester Medical Center, GI/ Hepatology Research Unit,
Rochester, NY
Benedict Maliakkal MD, Principal Investigator, Drug induced liver injury network: A multi-center, longitudinal study of
drug and CAM-induced liver injury.

5. 5 Curriculum Vitae
Emilty R. Pierce RN OCN CCRC
Lawrence, Saubermann MD, Principal Investigator, A double-blind, randomized, placebo-controlled multi-center study to assess the
safety and efficacy of AST-120 in mild to moderately active Crohn’s patients with fistulas.
Lawrence, Saubermann MD, Principle Investigator, A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the
Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Colitis (UC)
who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
Lawrence, Saubermann MD, Principal Investigator, A Phase III, multi-center, randomized, placebo controlled study to evaluate the
clinical efficacy and safety of induction and maintenance therapy with Abatacept in subject’s with active Crohn’s Disease who have
had an inadequate clinical response and/or intolerance to medical therapy.
Ullah, Asad MD, Principal Investigator, A study to investigate the effect of two doses of Creon on maldigestion in patients with
exocrine pancreatic insufficiency due to chronic pancreatitis.
Benedict Maliakkal MD, Principal Investigator, Randomized, placebo-controlled, multi-center study to assess the efficacy and safety
of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral
therapy (peginterferon alfa-2b plus ribavirin).
Parvez Mantry MD, Principal Investigator, Evaluation of the Cellular Immune Response in Patients with anti-SLA/LP- or anti-LKM-
positive Autoimmune Hepatitis.
Lawrence Saubermann MD, Principal Investigator, A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the
Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis
Benedict Maliakka MD, Principal Investigator, A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Co-infected with HIV
and Hepatitis C
Research Studies 2005-2007 AAIR Research Center, 300 Meridian Center, Rochester, NY
John Condemi MD, Principal Investigator, A phase II randomized, placebo controlled clinical trial to study the safety and efficacy of
Uvadex and Therakos Immune Cell Therapy Photopheresis System for patients with rheumatoid arthritis.
John Condemi MD, Principal Investigator, A multicenter, open label, continuation trial of Lymphosta-B antibody (monoclonal anti-
BlyS antibody) in subjects with systemic lupus erythematosus (SLE) who completed the phase II Protocol LBSL02
John Condemi MD, Principal Investigator, 13 week , multicenter, randomized double dummy, placebo controlled parallel group trial
of Lumiracoxib 100 mg in patients with primary osteoarthritis of the hip using celecoxib 200 mg qd as a positive control.
Emanuel Quaidoo MD, Principal Investigator, A randomized, double blind, double dummy, placebo-controlled, parallel-group study
in patients with active rheumatoid arthritis who currently have a partial clinical response to treatment with MTX.
John Condemi MD, Principal Investigator, A 26 week, randomized, double blind, parallel group, placebo controlled, multi-center
study to evaluate the effects of Omalizumab (Xolair™) on improving the tolerability of specific (cluster) immunotherapy in subjects
with persistent allergic asthma.
John Condemi MD, Principal Investigator, A Phase III trial assessing the efficacy and safety of Grazaz™ in subjects with seasonal
grass pollen induced rhino conjunctivitis with or without asthma.
Emmanuel Quaidoo MD, Principal Investigator, A 52 week, randomized, double blind, parallel group, multi-center, Phase IIIB study
comparing Symbicort™ pMDI 160/4.5mg x 2 actuations twice daily to Budesonide HFA pMDI 160mg x 2 actuations twice daily in
Adult/Adolescent African American subjects with asthma.
Peter Deane MD, Primary Investigator, A randomized, double-blind, parallel-group study of Cardiovascular safety in osteoarthritis or
rheumatoid arthritis patients with or at high risk for cardiovascular disease comparing celecoxib with naproxen and ibuprofen.
John Condemi MD, Principal Investigator, A multicenter, randomized, double-blind, triple dummy, placebo-controlle, parallel group
assessing the efficacy of fluticasone propionate aqueous nasal spray 200mcg QD versus montelukast 10mg QD in adolescent and
adult subjects with asthma and seasonal allergic rhinitis who are receiving Advair™ Diskus 100/50mcg BID or placebo BID.

6. 5 Curriculum Vitae
Emilty R. Pierce RN OCN CCRC
Lawrence, Saubermann MD, Principal Investigator, A double-blind, randomized, placebo-controlled multi-center study to assess the
safety and efficacy of AST-120 in mild to moderately active Crohn’s patients with fistulas.
Lawrence, Saubermann MD, Principle Investigator, A Phase III, Multi-Center, Randomized, Placebo-Controlled Study to Evaluate the
Clinical Efficacy and Safety of Induction and Maintenance Therapy with Abatacept in Subjects with Active Ulcerative Colitis (UC)
who have had an Inadequate Clinical Response and/or Intolerance to Medical Therapy
Lawrence, Saubermann MD, Principal Investigator, A Phase III, multi-center, randomized, placebo controlled study to evaluate the
clinical efficacy and safety of induction and maintenance therapy with Abatacept in subject’s with active Crohn’s Disease who have
had an inadequate clinical response and/or intolerance to medical therapy.
Ullah, Asad MD, Principal Investigator, A study to investigate the effect of two doses of Creon on maldigestion in patients with
exocrine pancreatic insufficiency due to chronic pancreatitis.
Benedict Maliakkal MD, Principal Investigator, Randomized, placebo-controlled, multi-center study to assess the efficacy and safety
of eltrombopag in thrombocytopenic subjects with hepatitis C virus (HCV) infection who are otherwise eligible to initiate antiviral
therapy (peginterferon alfa-2b plus ribavirin).
Parvez Mantry MD, Principal Investigator, Evaluation of the Cellular Immune Response in Patients with anti-SLA/LP- or anti-LKM-
positive Autoimmune Hepatitis.
Lawrence Saubermann MD, Principal Investigator, A Phase 3, Randomized, Placebo-Controlled, Blinded, Multicenter Study of the
Induction and Maintenance of Clinical Response and Remission by MLN0002 in Patients with Moderate to Severe Ulcerative Colitis
Benedict Maliakka MD, Principal Investigator, A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Co-infected with HIV
and Hepatitis C
Research Studies 2005-2007 AAIR Research Center, 300 Meridian Center, Rochester, NY
John Condemi MD, Principal Investigator, A phase II randomized, placebo controlled clinical trial to study the safety and efficacy of
Uvadex and Therakos Immune Cell Therapy Photopheresis System for patients with rheumatoid arthritis.
John Condemi MD, Principal Investigator, A multicenter, open label, continuation trial of Lymphosta-B antibody (monoclonal anti-
BlyS antibody) in subjects with systemic lupus erythematosus (SLE) who completed the phase II Protocol LBSL02
John Condemi MD, Principal Investigator, 13 week , multicenter, randomized double dummy, placebo controlled parallel group trial
of Lumiracoxib 100 mg in patients with primary osteoarthritis of the hip using celecoxib 200 mg qd as a positive control.
Emanuel Quaidoo MD, Principal Investigator, A randomized, double blind, double dummy, placebo-controlled, parallel-group study
in patients with active rheumatoid arthritis who currently have a partial clinical response to treatment with MTX.
John Condemi MD, Principal Investigator, A 26 week, randomized, double blind, parallel group, placebo controlled, multi-center
study to evaluate the effects of Omalizumab (Xolair™) on improving the tolerability of specific (cluster) immunotherapy in subjects
with persistent allergic asthma.
John Condemi MD, Principal Investigator, A Phase III trial assessing the efficacy and safety of Grazaz™ in subjects with seasonal
grass pollen induced rhino conjunctivitis with or without asthma.
Emmanuel Quaidoo MD, Principal Investigator, A 52 week, randomized, double blind, parallel group, multi-center, Phase IIIB study
comparing Symbicort™ pMDI 160/4.5mg x 2 actuations twice daily to Budesonide HFA pMDI 160mg x 2 actuations twice daily in
Adult/Adolescent African American subjects with asthma.
Peter Deane MD, Primary Investigator, A randomized, double-blind, parallel-group study of Cardiovascular safety in osteoarthritis or
rheumatoid arthritis patients with or at high risk for cardiovascular disease comparing celecoxib with naproxen and ibuprofen.
John Condemi MD, Principal Investigator, A multicenter, randomized, double-blind, triple dummy, placebo-controlle, parallel group
assessing the efficacy of fluticasone propionate aqueous nasal spray 200mcg QD versus montelukast 10mg QD in adolescent and
adult subjects with asthma and seasonal allergic rhinitis who are receiving Advair™ Diskus 100/50mcg BID or placebo BID.